Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy?

International Journal of Clinical Practice

Volumn 52, Issue 7, 1998, Pages 472-474

  Wu, C S ^a   Wang, S H ^a   Chen, P C ^a   Wu, V C C ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN DERIVATIVE; SULINDAC; TOLMETIN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS; FAMOTIDINE; FEMALE; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MISOPROSTOL; PROSPECTIVE STUDIES; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0031729926     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Collier DS, Pain JA. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Cut 1985; 26: 359-363.
2. Macintosh JH, Byth K, Piper DW. Environmental factors in aetiology of chronic gastric ulcer: a case control study of exposure variables before the first symptoms. Gut 1985; 26: 789-98.
3. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; i: 462-464.
4. Jick SS, Perara DR, Walker AM et al. Non-steroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. Lancet 1987; ii: 380-382.
5. Quader K, Logan RFA. Peptic ulcer (PU) deaths: how many occur at home or after non-steroidal anti-inflammatory drugs (NSAID) prescribing? Gut 1988; 29: A1443.
6. Griffin MR, Ray WA, Schaffner W. Non-steroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 96: 640-643.
7. Langman MJS. Epidemiological evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology 1989; 96: 640-643.
8. Fries JF, Miller SR, Spitz PW et al. Toward an epidemiology of gastropathy associated with non-steroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647-655.
9. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990; 300: 278-284.
10. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990; 12: 260-266.
11. Collins AJ, Davies J, St J Dixon A. Contrasting presentation and findings between patients with rheumatic complaints taking non-steroidal anti-inflammatory drugs and a general population referred for endoscopy. Br J Rheumatol 1986; 25: 50-53.
12. Matthewson K, Pugh S, Northfield TC. Which peptic ulcers bleed? Gut 1988; 29: 70-74.
13. Feldman M, Bamett CC. Gastric bicarbonate secretion in humans: effect of pentagastrin, bethanechol and 11,16,16-trimethyl prostaglandin E2. J Clin Invest 1983; 72: 295-303.
14. Hawkey CJ, Ramptom DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease or treatment? Gastroenterology 1985; 89: 1162-1188.
15. Wilson DE, Quaders E, Rajapaksa T et al. Effects of misoprostol on gastric acid and mucosal secretion in man. Dig Dis Sci 1986; 31(suppl): 1265-1295.
16. Isenberg JI, Hogan DL, Koss MA, Selling JA. Human duodenal mucosal bicarbonate secretion: evidence for basal secretion and stimulation by hydrochloric acid and a synthetic prostaglandin E1 analogue. Gastroenterology 1986; 91: 370-378.
17. Guth PH, Paulsen G, Nagata H. Histologic and microcirculatory changes in alcohol-induced gastric lesions in the rat: effect of prostaglandin cytoprotection. Gastroenterology 1984; 87: 1083-1090.
18. Sato N, Kawano S, Fukada M. The effect of misoprostol on gastric mucosal haemodynamics in man: a possible mechanism of cytoprotection. Gastroenterology 1986; 90: 1616-1623.
19. Lanza FL, Aspinall RL, Swabb EA et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988; 95: 289-294.
20. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; ii: 1277-1280.
21. Roth SH, Agrawal NM, Mahowald M et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149: 775-779.
22. Paladini G, Fabiani MG, Tosato F et al. Prophylactic and therapeutic role of misoprostol in NSAID-induced gastroduodenal lesions. Scan J Gastroenterol 1989; 24(suppl 164): 242-246.
23. Agrawal NM, Roth SH, Graham DY et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcers: a randomized, controlled trial. Ann Intern Med 1991; 115: 195-200.
24. Jaszewski R, Graham DY, Stromatt SC. Treatment of nonsteroidal anti-inflammatory drug-induced gastric ulcers with misoprostol: a double-blind multicenter study. Dig Dis Sci 1992; 37: 1820-1824.
25. Graham DY, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257-262.
26. Aabakken L, Bjornbeth BA, Weberg R et al. NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum? Aliment Pharmacol Therap 1990; 4: 295-303.
27. Bank S, Greenberg RE, Magier D, Lavin PT. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin-related ulcers. Clin Therap 1991; 13: 304-318.
28. Bank S, Blumstein M, Greenberg RE et al. Efficacy of famotidine in the healing of active benign gastric ulceration: comparison of nonsteroidal anti-inflammatory-or aspirin-induced gastric ulcer and idiopathic gastric ulceration. Long Island Jewish Medical Center Acid-Peptic Study Group. Clin Therap 1993; 15: 36-45.
29. Price HP, Fletcher M. Mechanisms of NSAID-induced gastroenteropathy. Drugs 1990; 40(suppl 5): 1-11.
30. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761-767.
31. Stern WR. Summary of the 33rd meeting of the Food and Drug Administration's Gastrointestinal Drugs Advisory Committee, September 1988. Am J Gastroenterol 1989; 84: 351-353.
32. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992; 87: 1398-1402.
33. Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients reveiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol 1994; 89: 203-207.
34. Henriksson K, Uribe A, Sandstedt B et al. Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci 1993: 38: 1688-1696.
35. Graham DY, Lidsky MD, Cox AM et al. Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991; 100: 1653-1657.
36. Lamothe PH, Rao E, Serra AJ et al. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcer: gastric PH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery. Gastroenterology 1991; 106(6): 1515-1520.